Page 1 | Search Results | Diabetes | American Diabetes Association

1-19 of 19

Sort by

Sort Order Select

Meeting Abstracts

1898-LB: Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation

KATHERINE G. GOMEZ, ALEJANDRA MACIAS PULIDO, ZOE B. MOLINA, MARIA NUNEZ, MARCUS HOMPESCH

Diabetes 2024;74(Supplement_1):1898-LB

https://doi.org/10.2337/db25-1898-LB

Published: 20 June 2025

View articletitled, 1898-LB: Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation

Meeting Abstracts

1980-LB: Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study

ALEJANDRA MACIAS PULIDO, MARCUS HOMPESCH

Diabetes 2024;74(Supplement_1):1980-LB

https://doi.org/10.2337/db25-1980-LB

Published: 20 June 2025

View articletitled, 1980-LB: Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study

Journal Articles

A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes

Anika Bilal, Anna Casu, Fanchao Yi, Tumpa Dutta, Justine M. Mucinski, Gina Mercouffer, Martin C. Marak, Marcus Hompesch, David Kelley, Richard E. Pratley

Diabetes 2025;74(7):1262–1272

https://doi.org/10.2337/db25-0096

Published: 02 April 2025

View articletitled, A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes

Meeting Abstracts

774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

MANU CHAKRAVARTHY, MOISES HERNANDEZ, MICHAEL ELLIOTT, ALEJANDRA MACIAS, STIG K. HANSEN, MARCUS HOMPESCH

Diabetes 2023;72(Supplement_1):774-P

https://doi.org/10.2337/db23-774-P

Published: 20 June 2023

View articletitled, 774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

Meeting Abstracts

805-P: Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp

MARCUS HOMPESCH, FIONA J. LAWRENCE, JAN JEZEK, DAVID J. GERRING, THOMAS PIEBER

Diabetes 2023;72(Supplement_1):805-P

https://doi.org/10.2337/db23-805-P

Published: 20 June 2023

View articletitled, 805-P: Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp

Meeting Abstracts

765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)

MI-KYUNG KIM, DAE YOUNG LEE, JIYOON JEONG, MICHAEL GRIMM, BRIDGETTE B. FRANEY, MARCUS HOMPESCH

Diabetes 2021;70(Supplement_1):765-P

https://doi.org/10.2337/db21-765-P

Published: 01 June 2021

View articletitled, 765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)

Meeting Abstracts

766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)

MI-KYUNG KIM, DAE YOUNG LEE, JIYOON JEONG, MICHAEL GRIMM, BRIDGETTE B. FRANEY, MARCUS HOMPESCH

Diabetes 2021;70(Supplement_1):766-P

https://doi.org/10.2337/db21-766-P

Published: 01 June 2021

View articletitled, 766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)

Meeting Abstracts

901-P: Evaluation of the Analytical Performance of YSI 2900D Compared with YSI 2300 STAT Plus for Glucose Concentration Measurements

MOISES HERNANDEZ, CARINE BEYSEN, MARCUS HOMPESCH, LINDA MORROW

Diabetes 2020;69(Supplement_1):901-P

https://doi.org/10.2337/db20-901-P

Published: 01 June 2020

View articletitled, 901-P: Evaluation of the Analytical Performance of YSI 2900D Compared with YSI 2300 STAT Plus for Glucose Concentration Measurements

Meeting Abstracts

107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)

LINDA MORROW, MICHAEL GRIMM, CARINE BEYSEN, GEOFFREY WALFORD, KELLY DUNCAN, PRANAB K. MITRA, PAVAN VADDADY, MARCUS HOMPESCH

Diabetes 2020;69(Supplement_1):107-LB

https://doi.org/10.2337/db20-107-LB

Published: 01 June 2020

View articletitled, 107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)

Meeting Abstracts

106-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Subjects with T1DM and T2DM

LINDA MORROW, MICHAEL GRIMM, CARINE BEYSEN, GEOFFREY WALFORD, KELLY DUNCAN, PRANAB K. MITRA, PAVAN VADDADY, MARCUS HOMPESCH

Diabetes 2020;69(Supplement_1):106-LB

https://doi.org/10.2337/db20-106-LB

Published: 01 June 2020

View articletitled, 106-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Subjects with T1DM and T2DM

Meeting Abstracts

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):53-OR

https://doi.org/10.2337/db19-53-OR

Published: 01 June 2019

View articletitled, 53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Meeting Abstracts

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

RICHARD E. PRATLEY, STEPHAN JACOB, JAHOON KANG, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, OAKPIL HAN, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):1001-P

https://doi.org/10.2337/db19-1001-P

Published: 01 June 2019

View articletitled, 1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Meeting Abstracts

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

JULIO ROSENSTOCK, CRISTOBAL MORALES, SR., ULRICH WENDISCH, GEORGE E. DAILEY, III, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):1014-P

https://doi.org/10.2337/db19-1014-P

Published: 01 June 2019

View articletitled, 1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Meeting Abstracts

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

GEORGE E. DAILEY, III, JULIO ROSENSTOCK, CRISTOBAL MORALES, SR., ULRICH WENDISCH, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, CHRISTOPHER H. SORLI, IKE OGBAA, JOHN A. STEWART, KUN-HO YOON

Diabetes 2019;68(Supplement_1):1023-P

https://doi.org/10.2337/db19-1023-P

Published: 01 June 2019

View articletitled, 1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Meeting Abstracts

982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

JAE DUK CHOI, SEUNGJAE BAEK, YOUNGMIN KIM, KAHEE EUN, SE CHANG KWON, LINDA MORROW, MARCUS HOMPESCH, JAHOON KANG

Diabetes 2019;68(Supplement_1):982-P

https://doi.org/10.2337/db19-982-P

Published: 01 June 2019

View articletitled, 982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

Meeting Abstracts

The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes

RICHARD E. PRATLEY, JAHOON KANG, IN YOUNG CHOI, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, KUN-HO YOON, CHRISTOPHER H. SORLI

Diabetes 2018;67(Supplement_1):2300-PUB

https://doi.org/10.2337/db18-2300-PUB

Published: 01 July 2018

View articletitled, The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes

Meeting Abstracts

Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies

JULIO ROSENSTOCK, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, KUN-HO YOON, CHRISTOPHER H. SORLI

Diabetes 2018;67(Supplement_1):1111-P

https://doi.org/10.2337/db18-1111-P

Published: 01 July 2018

View articletitled, Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies

Meeting Abstracts

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

IN YOUNG CHOI, MI JIN MOON, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI

Diabetes 2018;67(Supplement_1):1090-P

https://doi.org/10.2337/db18-1090-P

Published: 01 July 2018

View articletitled, In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

Meeting Abstracts

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

YOUNG JIN PARK, IN YOUNG CHOI, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI

Diabetes 2018;67(Supplement_1):1091-P

https://doi.org/10.2337/db18-1091-P

Published: 01 July 2018

View articletitled, Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

1898-LB: Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation

1980-LB: Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study

A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes

774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

805-P: Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp

765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)

766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)

901-P: Evaluation of the Analytical Performance of YSI 2900D Compared with YSI 2300 STAT Plus for Glucose Concentration Measurements

107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)

106-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Subjects with T1DM and T2DM

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes

Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only